Income Statement (IVERIC/BIO)

Technical Analysis Historical Data Financials News & Analysis

IVERIC/BIO NEWS

Clearside Biomedical Declares Fourth Quarter and Complete 12 months 2024 Monetary Effects and Gives Company Replace By Site Author - 1 month ago

- Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partners New Drug Application for ARCATUS®(XIPERE®) for Uveitic Macular Edem… [+16915 chars]...

Read more
Top Stock
CurrencyPrice Chg
BA 		182.3 4.35
2.44%
CVX 		140.1 1.37
0.99%
CAT 		307.06 0.61
0.2%
INTC 		20.51 0.46
2.29%
MSFT 		391.16 -0.69
-0.18%
DIS 		90.16 -0.12
-0.13%
DOW 		29.95 -0.07
-0.23%
CSCO 		56.84 0.13
0.23%
GS 		546.4 1.54
0.28%